Recently, the macro environment of the pharmaceutical industry has changed rapidly. The fast development of digital-intelligence technology is deeply reshaping the underlying logic and business models of China's healthcare industry. Applications of new technologies such as artificial intelligence and big data are providing pharma and medtech companies with more innovation opportunities and development possibilities, while bringing unprecedented change to patients, doctors, and the entire healthcare industry. Against this background, the 12th CIAPH Digital Healthcare Industry Forum was held in Shanghai from March 21 to 22, 2024.
As a comprehensive and long-term digital-intelligence partner for the life sciences industry, MeDomino Partner Guo Wenping was invited to attend and delivered a speech titled "Implementation Case: Innovative AI Leads a New Direction for Enterprise Marketing Compliance."
MeDomino Partner Guo Wenping delivered a speech
Guo Wenping said: "MeDomino's next-generation AI intelligent customer experience platform, NICE (Next Intelligent Customer Experience), helps enterprises achieve comprehensive compliance, precision, and effectiveness in areas such as internal and external customer data integration, customer data insights, integrated content management, intelligent generation and approval, and consistent implementation of marketing and medical strategies, bringing HCPs a new interactive experience upgrade."
As Guo Wenping noted, the CIAPH theme of "pragmatic digital transformation" aligns closely with MeDomino's long-held value proposition: bringing definite business value to pharma and medtech companies.
Indeed, the NICE solution launched by MeDomino in 2023 integrates a customer data center, UCH (Unified Customer Hub), customer tag platform, content management center, and strategy center, while also connecting meeting systems and automated distribution channels. It enables precise assignment and one-click distribution of marketing and medical strategies. While upgrading the HCP experience, it also helped a leading European pharmaceutical company achieve the best HCP-content matching strategy and improve the effective reach rate of digital-channel content by more than tenfold.
Currently, MeDomino has established ongoing cooperation with 95% of the world's top 20 pharmaceutical companies, as well as several global leading medical device companies. In the future, we will continue to stay on the path of digital-intelligent transformation in the life sciences industry, helping more client enterprises drive business growth and improve efficiency.
